SNN heads into its May 13 interim results with the borrow market at its tightest in a year — and options traders growing more defensive by the day.
The lending picture is the sharpest signal. Availability on SNN shares has collapsed to effectively zero, with the borrow pool fully lent out for the second consecutive session — matching the 52-week extreme last seen in late March. That tightness has arrived alongside a rapid build in short positions: shares short have risen 22% over the past month to around 3.8 million, with a 14% jump in the past week alone. Borrowing costs have eased slightly to 4.26% — down about 7% on the week — but they remain elevated for a large-cap medical device name and show no signs of returning to the lows recorded earlier in April. Days to cover run at roughly four, meaning unwinding the current short position against normal volume would take the better part of a trading week.
Options positioning reinforces the cautious lean. The put/call ratio has moved notably above its recent baseline, running at 0.26 against a 20-day average of around 0.20 — a gap that represents nearly three standard deviations, the highest defensive skew in the options market since at least the start of the year. The options shift has come as the stock has shed more than 5% over the past month to close at $29.95, including a 3.9% drop on the week. Past earnings reactions add texture: the last confirmed print in early March triggered a modest 0.4% one-day decline but a sharper 7.6% five-day pullback — a pattern consistent with the stock digesting guidance over several sessions rather than reacting violently on the day.
The debate among analysts has leaned cautious for some time. Bernstein downgraded the stock to Market Perform in October 2025, and UBS moved to Neutral in March 2025 after holding a Buy rating since mid-2024. Canaccord Genuity, the most active covering firm, has held a steady Hold rating through multiple target adjustments, most recently lifting its target to $35 — still roughly 17% above current levels, but well below the consensus mean of ~$48 that appears to reflect stale pre-2022 data. The bull case centres on 5%-plus underlying growth in orthopaedics, strong US traction in enabling technologies like CORI, and margin expansion in the second half of 2025. Bears point to persistent China headwinds from inventory destocking and regulatory uncertainty, structurally lower returns in the orthopaedic segment versus sports medicine and wound care, and the risk of US reimbursement pressure in a shifting healthcare landscape. One genuinely interesting ownership development: activist investor Cevian Capital holds 10.7% of shares — the single largest position — and added nearly 14.7 million shares in the most recent reported period, signalling continued confidence in a turnaround thesis that the stock's recent price action has not yet validated.
Wednesday's print is therefore a test of whether management's promised second-half margin improvement is materialising, and whether Chinese market conditions have stabilised enough to avoid another guidance cut.
See the live data behind this article on ORTEX.
Open SNN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
